Skip to content
10-Q

Quarterly Report

FATE THERAPEUTICS, INC. FATE

0001193125-26-220696

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 116.56M sh
Shares Diluted Q1 2026 · Mar 31, 2026 120.03M sh
Shares Diluted Q1 2026 · Mar 31, 2025 118.38M sh
Capex Q1 2026 · Mar 31, 2026 $239K
Capex Q1 2026 · Mar 31, 2025 $1.2M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$30.82M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$33.81M
Short Term Investments Q1 2026 · Mar 31, 2026 $135.25M
Short Term Investments Q1 2026 · Dec 31, 2025 $157.03M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $39.57M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $46.63M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $44.92M
Stockholders Equity Q1 2026 · Mar 31, 2026 $179.71M
Stockholders Equity Q1 2026 · Dec 31, 2025 $207.18M
Stockholders Equity Q1 2026 · Mar 31, 2025 $288.41M
Stockholders Equity Q1 2026 · Dec 31, 2024 $318.73M
Current Liabilities Q1 2026 · Mar 31, 2026 $30.69M
Current Liabilities Q1 2026 · Dec 31, 2025 $36.07M
Current Assets Q1 2026 · Mar 31, 2026 $179.53M
Current Assets Q1 2026 · Dec 31, 2025 $208.7M
Total Assets Q1 2026 · Mar 31, 2026 $284.92M
Total Assets Q1 2026 · Dec 31, 2025 $318.94M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.26
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.32
Eps Basic Q1 2026 · Mar 31, 2026 −$0.26
Eps Basic Q1 2026 · Mar 31, 2025 −$0.32
Sga Expense Q1 2026 · Mar 31, 2026 $9.6M
Sga Expense Q1 2026 · Mar 31, 2025 $13.77M
Rd Expense Q1 2026 · Mar 31, 2026 $24.7M
Rd Expense Q1 2026 · Mar 31, 2025 $29.14M
Net Income Q1 2026 · Mar 31, 2026 −$31.21M
Net Income Q1 2026 · Mar 31, 2025 −$37.62M
Operating Income Q1 2026 · Mar 31, 2026 −$33M
Operating Income Q1 2026 · Mar 31, 2025 −$41.28M
Revenue Q1 2026 · Mar 31, 2026 $1.3M
Revenue Q1 2026 · Mar 31, 2025 $1.63M